Prevalence and clinical implications of testosterone deficiency in men with end-stage renal disease

Nephrology Dialysis Transplantation

Volumn 26, Issue 1, 2011, Pages 184-190

  Carrero, Juan Jesús ^a   Qureshi, Abdul Rashid ^a   Nakashima, Ayumu ^a   Arver, Stefan ^a   Parini, Paolo ^a   Lindholm, Bengt ^a   Bárány, Peter ^a   Heimbürger, Olof ^a   Stenvinkel, Peter ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

endocrine dysfunction; haemodialysis; risk factor; sex hormones

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; INTERLEUKIN 6; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; AGED; ANDROGEN DEFICIENCY; ARTICLE; CARDIOVASCULAR DISEASE; COMORBIDITY; CORRELATION ANALYSIS; FEMALE; HUMAN; INFLAMMATION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREVALENCE; PRIORITY JOURNAL; TESTOSTERONE BLOOD LEVEL;

AGED; CARDIOVASCULAR DISEASES; COHORT STUDIES; COMORBIDITY; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDIES; RENAL DIALYSIS; TESTOSTERONE;

EID: 78650630599     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq397     Document Type: Article

References (43)

1. De Jager DJ, Grootendorst DC, Jager KJ et al. Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA 2009; 302: 1782-1789
2. Handelsman DJ. Hypothalamic-pituitary gonadal dysfunction in renal failure, dialysis and renal transplantation. Endocr Rev 1985; 6: 151-182
3. Carrero JJ, Qureshi AR, Axelsson J et al. Clinical and biochemical implications of low thyroid hormone levels (total and free forms) in euthyroid patients with chronic kidney disease. J Intern Med 2007; 262: 690-701
4. Schmidt A, Luger A, Horl WH. Sexual hormone abnormalities in male patients with renal failure. Nephrol Dial Transplant 2002; 17: 368-371
5. Dunkel L, Raivio T, Laine J et al. Circulating luteinizing hormone receptor inhibitor(s) in boys with chronic renal failure. Kidney Int 1997; 51: 777-784
6. Palmer BF. Outcomes associated with hypogonadism in men with chronic kidney disease. Adv Chron Kidney Dis 2004; 11: 342-347
7. Brockenbrough AT, Dittrich MO, Page ST et al. Transdermal andro-gen therapy to augment EPO in the treatment of anemia of chronic renal disease. Am J Kidney Dis 2006; 47: 251-262
8. Traish AM, Saad F, Feeley RJ et al. The dark side of testosterone deficiency: III. Cardiovascular disease. J Androl 2009; 30: 477-494
9. Khaw KT, Dowsett M, Folkerd E et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 2007; 116: 2694-2701
10. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 2008; 93: 68-75
11. Carrero JJ, Qureshi AR, Parini P et al. Low serum testosterone increases mortality risk among male dialysis patients. J Am Soc Nephrol 2009; 20: 613-620
12. Doumouchtsis KK, Kostakis AI, Doumouchtsis SK et al. The effect of sexual hormone abnormalities on proximal femur bone mineral density in hemodialysis patients and the possible role of RANKL. Hemodial Int 2008; 12: 100-107
13. Karakitsos D, Patrianakos AP, De Groot E et al. Androgen deficiency and endothelial dysfunction in men with end-stage kidney disease receiving maintenance hemodialysis. Am J Nephrol 2006; 26: 536-543
14. Albaaj F, Sivalingham M, Haynes Pet al. Prevalence of hypogonadism in male patients with renal failure. Postgrad Med J 2006; 82: 693-696
15. Johansen KL. Testosterone metabolism and replacement therapy in patients with end-stage renal disease. Semin Dial 2004; 17: 202-208
16. Bhasin S, Cunningham GR, Hayes FJ et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006; 91: 1995-2010
17. Stenvinkel P, Heimburger O, Paultre F et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999; 55: 1899-1911
18. Carrero JJ, Qureshi AR, Axelsson J et al. Comparison of nutritional and inflammatory markers in dialysis patients with reduced appetite. Am J Clin Nutr 2007; 85: 695-701
19. Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab 2006; 91: 4335-4343
20. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999; 84: 3666-3672
21. Heinzl H, Kaider A. Gaining more flexibility in Cox proportional hazards regression models with cubic spline functions. Comput Meth Programs Biomed 1997; 54: 201-208
22. Harrell FE Jr, Lee KL, Califf RM et al. Regression modelling strategies for improved prognostic prediction. Stat Med 1984; 3: 143-152
23. Tostain JL, Blanc F. Testosterone deficiency: a common, unrecognized syndrome. Nat Clin Pract Urol 2008; 5: 388-396
24. Araujo AB, Esche GR, Kupelian Vet al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab 2007; 92: 4241-4247
25. Lunenfeld B, Saad F, Hoesl CE. ISA, ISSAM and EAU recommendations for the investigation, treatment and monitoring of late-onset hypogonadism in males: scientific background and rationale. Aging Male 2005; 8: 59-74
26. Vermeulen A, Kaufman JM. Diagnosis of hypogonadism in the aging male. Aging Male 2002; 5: 170-176
27. Singh AB, Norris K, Modi N et al. Pharmacokinetics of a transder-mal testosterone system in men with end stage renal disease receiving maintenance hemodialysis and healthy hypogonadal men. J Clin Endocrinol Metab 2001; 86: 2437-2445
28. De Vries CP, Gooren LJ, Oe PL. Haemodialysis and testicular function. Int J Androl 1984; 7: 97-103
29. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005; 26: 833-876
30. DeLong M, Logan JL, Yong KC et al. Renin-angiotensin blockade reduces serum free testosterone in middle-aged men on haemodialysis and correlates with erythropoietin resistance. Nephrol Dial Transplant 2005; 20: 585-590
31. Svartberg J. Androgens and chronic obstructive pulmonary disease. Curr Opin Endocrinol Diab Obes 2010; 17: 257-261
32. Malkin CJ, Jones TH, Channer KS. Testosterone in chronic heart failure. Front Horm Res 2009; 37: 183-196
33. Malkin CJ, Pugh PJ, Jones RD et al. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab 2004; 89: 3313-3318
34. Kapoor D, Clarke S, Stanworth R et al. The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2007; 156: 595-602
35. Johansen KL. Anabolic and catabolic mechanisms in end-stage renal disease. Adv Chron Kidney Dis 2009; 16: 501-510
36. Anker SD, Chua TP, Ponikowski P et al. Hormonal changes and cata-bolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997; 96: 526-534
37. Muller M, van der Schouw YT, Thijssen JH et al. Endogenous sex hormones and cardiovascular disease in men. J Clin Endocrinol Metab 2003; 88: 5076-5086
38. Foresta C, Caretta N, Lana A et al. Reduced number of circulating endothelial progenitor cells in hypogonadal men. J Clin Endocrinol Metab 2006; 91: 4599-4602
39. Foresta C, Zuccarello D, De Toni L et al. Androgens stimulate endo-thelial progenitor cells through an androgen receptor-mediated pathway. Clin Endocrinol (Oxf) 2008; 68: 284-289
40. Webb CM, Elkington AG, Kraidly MM et al. Effects of oral testosterone treatment on myocardial perfusion and vascular function in men with low plasma testosterone and coronary heart disease. Am J Cardiol 2008; 101: 618-624
41. Johansen KL, Painter PL, Sakkas GK et al. Effects of resistance exercise training and nandrolone decanoate on body composition and muscle function among patients who receive hemodialysis: a randomized, controlled trial. J Am Soc Nephrol 2006; 17: 2307-2314
42. Johansen KL, Mulligan K, SchambelanM. Anabolic effectsof nandro-lone decanoate in patients receiving dialysis: a randomized controlled trial. JAMA 1999; 281: 1275-1281
43. Avesani CM, Carrero JJ, Axelsson J et al. Inflammation and wasting in chronic kidney disease: partners in crime. Kidney Int 2006; 70: S8-S13